Observational studyMedicine2025
The effect of circulating CD4+ and CD8+ T cells on the prognosis in advanced postoperative pancreatic adenocarcinoma patients who received chemotherapy.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to analyze the impact of circulating immune cells before and after chemotherapy on the prognosis of patients with advanced pancreatic adenocarcinoma (PAC). Data were collected from 74 advanced PAC patients with post-chemotherapy, retrieved from the Affiliated Hospital of Nantong University database in Jiangsu. Based on the cutoff values of circulating CD4+ and CD8+ T cells before and after chemotherapy, the aforementioned patients were divided into high- and low-level groups. The impact of the expression levels of blood immune cells before and after chemotherapy on patient prognosis was analyzed separately. For both pre- and post-treatment circulating CD4+ and CD8+ T cells, patients in the high expression group had significantly better progression-free survival and overall survival than those in the low expression group (P < .001). The results of this study show that high circulating immune cells are positively associated with better prognosis in patients with advanced PAC receiving chemotherapy and may become a new prognostic indicator for PAC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.